TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07518329: A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells

Sponsor: Arovella Therapeutics Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,817,272

Rescue Site Savings

+$4,492,488

Unlock Full NCT07518329 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07518329 Rescue Dossier →